NK cell receptors and their ligands in leukemia (Q37018656)

17 August 2017

1 reference

title

NK cell receptors and their ligands in leukemia (English)

1 reference

17 August 2017

1 reference

Verheyden S

1 reference

17 August 2017

Demanet C

series ordinal

1 reference

17 August 2017

language of work or name

1 reference

29 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

249-257

1 reference

Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Identification of natural killer cell receptor phenotypes associated with leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

HLA-G class I gene expression in normal and malignant hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Genomic polymorphism and allogeneic hematopoietic transplantation outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Licensing of natural killer cells by host major histocompatibility complex class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Novel approaches using natural killer cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The Role of Autologous Natural Killer Cells in Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Interleukin-2 and interleukin-15: immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Susceptibility to myeloid and lymphoid leukemia is mediated by distinct inhibitory KIR-HLA ligand interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5- B cells in patients with chronic lymphocytic leukaemia (CLL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Lack of HLA-E surface expression is due to deficiency of HLA-E transcripts in the malignant hematopoietic cells of leukemic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Increased Infection-Related Mortality in KIR-Ligand???Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Relevance of KIR gene polymorphisms in bone marrow transplantation outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405040

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405040

1 reference

Dimensions Publication ID

17 August 2017

1022531733

0 references

1 reference